Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Stock Price

ARQTStock

$24.86+55.02%52W

Market Cap$3.12B

P/E—

PEG Ratio—

Div yield—

Beta1.59

ARQT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-18.47%

Price vs S&P 500 (4W)-15.86%

VGM Score55.60

Book Value / Share (Quarterly)$1.76

P/TBV (Annual)20.37x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)367.11%

Cash Flow / Share (Quarterly)$0.31

Price vs S&P 500 (YTD)-26.63%

Gross Margin (TTM)91.14%

Net Profit Margin (TTM)6.15%

EPS (TTM)$0.21

10-Day Avg Trading Volume1.62M

EPS Excl Extra (TTM)$0.21

EPS (Annual)$-0.13

ROI (Annual)-5.41%

Gross Margin (Annual)90.24%

Net Profit Margin (5Y Avg)-19390.75%

Cash / Share (Quarterly)$1.90

P/E Basic Excl Extra (TTM)113.86x

Revenue Growth QoQ (YoY)59.33%

ROA (Last FY)-3.73%

Revenue Growth TTM (YoY)76.11%

EBITD / Share (TTM)$0.26

ROE (5Y Avg)-122.20%

Operating Margin (TTM)7.38%

Cash Flow / Share (Annual)$-0.13

P/B Ratio14.72x

P/B Ratio (Quarterly)14.87x

Net Income / Employee (Annual)$-45,600

EV / Revenue (TTM)7.16x

Net Interest Coverage (TTM)-3.70x

ROA (TTM)6.51%

EV / EBITDA (TTM)96.99x

EPS Incl Extra (Annual)$-0.13

Current Ratio (Annual)3.17x

Quick Ratio (Quarterly)2.46x

3-Month Avg Trading Volume1.72M

52-Week Price Return55.02%

P/E Incl Extra (TTM)113.86x

Revenue / Employee (TTM)$1,310,700

Tangible BV / Share (Quarterly)$1.65

P/S Ratio (Annual)8.63x

Asset Turnover (Annual)0.87x

52-Week High$31.77

Operating Margin (5Y Avg)-19198.81%

EPS Excl Extra (Annual)$-0.13

CapEx CAGR (5Y)101.71%

Tangible BV CAGR (5Y)147.92%

26-Week Price Return-7.23%

Quick Ratio (Annual)2.83x

13-Week Price Return17.94%

Total Debt / Equity (Annual)0.57x

Current Ratio (Quarterly)2.92x

Enterprise Value$3.32B

Asset Turnover (TTM)1.06x

Book Value / Share Growth (5Y)-24.47%

Revenue / Employee (Annual)$1,062,400

Inventory Turnover (Annual)1.98x

Pretax Margin (Annual)-3.98%

Cash / Share (Annual)$1.79

3-Month Return Std Dev40.92%

Net Income / Employee (TTM)$80,600

ROE (Last FY)-8.52%

Net Interest Coverage (Annual)2.82x

EPS Basic Excl Extra (Annual)$-0.13

Receivables Turnover (TTM)3.54x

EV / Free Cash Flow (TTM)84.85x

Total Debt / Equity (Quarterly)0.49x

EPS Incl Extra (TTM)$0.21

Receivables Turnover (Annual)3.43x

ROI (TTM)9.56%

P/S Ratio (TTM)7.00x

Pretax Margin (5Y Avg)-19390.75%

Revenue / Share (Annual)$2.96

Tangible BV / Share (Annual)$1.42

Forward P/E43.33x

Price vs S&P 500 (52W)36.71%

P/E Ratio (TTM)113.86x

Year-to-Date Return-14.67%

5-Day Price Return-6.63%

EPS Normalized (Annual)$-0.13

ROA (5Y Avg)-48.11%

Net Profit Margin (Annual)-4.29%

Month-to-Date Return-7.74%

Cash Flow / Share (TTM)$-4.34

EBITD / Share (Annual)$-0.10

Operating Margin (Annual)-3.25%

LT Debt / Equity (Annual)0.57x

P/CF (TTM)82.61x

ROI (5Y Avg)-56.15%

P/E Excl Extra (TTM)113.86x

LT Debt / Equity (Quarterly)0.46x

EPS Basic Excl Extra (TTM)$0.21

P/TBV (Quarterly)15.85x

P/B Ratio (Annual)18.77x

Inventory Turnover (TTM)1.49x

Pretax Margin (TTM)6.31%

Book Value / Share (Annual)$1.54

Price vs S&P 500 (13W)15.15%

Beta1.59x

Revenue / Share (TTM)$3.41

ROE (TTM)15.05%

52-Week Low$15.10

vGradeD

gGradeA

mGradeB

vgmGradeC

ARQT Earnings Surprise History

Q2 25-0.13est. -0.16

Q3 250.06est. -0.09

Q4 250.13est. 0.09

Q1 26-0.09est. -0.06

Q2 260.11est. 0.05

ARQT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ARQTArcutis Biotherapeutics, Inc. Common Stock	D	A	B	$24.86
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Arcutis Biotherapeutics, Inc. Common Stock

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company developing topical and systemic treatments for immune-mediated dermatological diseases with significant unmet medical needs. Its lead candidate, ZORYVE (roflumilast cream), has completed Phase 3 trials in plaque psoriasis, demonstrating efficacy and favorable tolerability. The company operates in the dermatology space with a differentiated product portfolio focused on this therapeutic area.